Payment overview · 2025
General Payments
$851.08
41 reported records · 16 companies
Healthcare provider profile · identity verified
Rolando Gutierrez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MENIFEE, CA · NPI 1104841212
Verified facts
What the public records show
CMS Open Payments records show Rolando Gutierrez, M.D. received $851.08 in general payments during 2025 across 41 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $188.69 | 22.2% | 11 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $110.23 | 12.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $96.56 | 11.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.87 | 10.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.74 | 6.7% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.08 | 6.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.10 | 5.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $49.06 | 5.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.52 | 5.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.00 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.57 | 2.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.99 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.91 | 1.9% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.54 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.82 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.40 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $851.08 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $168.31 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $145.62 | 7 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $110.23 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.96 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $56.74 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $53.08 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.69 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
173 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
253 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1017 | 297 |
| Amlodipine Besylate | Amlodipine Besylate | 550 | 153 |
| Metformin Hcl | Metformin Hcl | 542 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 538 | 146 |
| Losartan Potassium | Losartan Potassium | 456 | 128 |
| Gabapentin | Gabapentin | 437 | 119 |
| Lisinopril | Lisinopril | 401 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 372 | 108 |
| Omeprazole | Omeprazole | 362 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 68 |
| Simvastatin | Simvastatin | 259 | 73 |
| Eliquis | Apixaban | 253 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 59 |
| Furosemide | Furosemide | 244 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 50 |
| Famotidine | Famotidine | 211 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 46 |
| Montelukast Sodium | Montelukast Sodium | 202 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 59 |
| Potassium Chloride | Potassium Chloride | 191 | 41 |
| Carvedilol | Carvedilol | 190 | 44 |
| Trazodone Hcl | Trazodone Hcl | 174 | 34 |
| Ozempic | Semaglutide | 173 | 29 |
| Tramadol Hcl | Tramadol Hcl | 170 | 56 |
| Alprazolam | Alprazolam | 165 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 59 |
| Alendronate Sodium | Alendronate Sodium | 155 | 36 |
| Glipizide | Glipizide | 143 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 44 |
| Lorazepam | Lorazepam | 136 | 28 |
| Ibuprofen | Ibuprofen | 135 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 30 |
| Pregabalin | Pregabalin | 102 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 35 |
| Sertraline Hcl | Sertraline Hcl | 101 | 36 |
| Temazepam | Temazepam | 101 | 25 |
| Donepezil Hcl | Donepezil Hcl | 99 | 26 |
| Atenolol | Atenolol | 96 | 31 |
| Benazepril Hcl | Benazepril Hcl | 94 | 30 |
| Allopurinol | Allopurinol | 93 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 28 |
| Bupropion Xl | Bupropion Hcl | 90 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 69 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 17 |
| Finasteride | Finasteride | 66 | 21 |
| Januvia | Sitagliptin Phosphate | 62 | 15 |
| Spironolactone | Spironolactone | 61 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 16 |
| Baclofen | Baclofen | 56 | suppressed |
| Memantine Hcl | Memantine Hcl | 55 | 12 |
| Meloxicam | Meloxicam | 53 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Celecoxib | Celecoxib | 52 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 12 |
| Jardiance | Empagliflozin | 47 | 18 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 42 |
| Prednisone | Prednisone | 44 | 15 |
| Ezetimibe | Ezetimibe | 42 | 11 |
| Latanoprost | Latanoprost | 42 | 15 |
| Valsartan | Valsartan | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 31 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Mirtazapine | Mirtazapine | 41 | 12 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 38 | 23 |
| Nifedipine Er | Nifedipine | 38 | 11 |
| Clonidine Hcl | Clonidine Hcl | 37 | 20 |
| Divalproex Sodium | Divalproex Sodium | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 31 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 13 |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Azithromycin | Azithromycin | 33 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | 11 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 12 |
| Cephalexin | Cephalexin | 28 | 23 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Linzess | Linaclotide | 25 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 13 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 14 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Rytary | Carbidopa/Levodopa | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nystatin | Nystatin | 17 | 14 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 11 |
| Clonidine | Clonidine | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Kesimpta Pen | Ofatumumab | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $851.08 · 41 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENTRESTO, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, LEQVIO, MOUNJARO, NEMLUVIO, NURTEC ODT, REXULTI, SHINGRIX, TRELEGY ELLIPTA, Tlando, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error